The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia
Open accessAbstract
BACKGROUND: Progressive volumetric changes in the brains of people with schizophrenia have been attributed to a number of factors. AIMS: To determine whether glutamatergic changes in patients with schizophrenia correlated with grey-matter losses during the first years of illness. METHOD: Left anterior cingulate and thalamic glutamatergic metabolite levels and grey-matter volumes were examined in 16 patients with first-episode schizophrenia before and after 10 months and 30 months of antipsychotic treatment and in 16 healthy participants on two occasions 30 months apart. RESULTS: Higher than normal glutamine levels were found in the anterior cingulate and thalamus of never-treated patients. Thalamic levels of glutamine were significantly reduced after 30 months. Limited grey-matter reductions were seen in patients at 10 months followed by widespread grey-matter loss at 30 months. Parietal and temporal lobe grey-matter loss was correlated with thalamic glutamine loss. CONCLUSIONS: Elevated glutamine levels in never-treated patients followed by decreased thalamic glutamine and grey-matter loss in connected regions could indicate either neurodegeneration or a plastic response to reduced subcortical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, long-lasting effects of antipsychotic medication have not been found in human studies so far.28,34”
From Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies (2013) · cites this paper as [34]
In the citing paper
“A longitudinal study which assessed patients when medicationnaive and after treatment found reductions in precuneal gray matter after 10 months and in frontal, temporal, parietal, and limbic lobes after 30 months of treatment, which was correlated with thalamic glutamine reductions.34”
From Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies (2013) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Multivariate Statistics for the Social Sciences
Stevens, J. P. (2012) · Routledge eBooks · doi:10.4324/9780203843130 · Cited by 10,652
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676
Structured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 3,582
Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1997) · American Psychiatric Press eBooks · Cited by 3,101
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,710
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Alexander, G. E., Crutcher, M. D., & DeLong, M. R. (1990) · PubMed · Cited by 2,422
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
(1991) · Progress in Brain Research · doi:10.1016/s0079-6123(08)62678-3 · Cited by 1,961
Flagged first, then by citations
Cited by
Sorted by citations
Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
A systematic review of the effects of antipsychotic drugs on brain volume
Moncrieff, J., & Leo, J. (2010) · Psychological Medicine · doi:10.1017/s0033291709992297 · Cited by 312
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania
Öngür, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M. Y., Cohen, B. M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.014 · Cited by 272
Metadata
- Authors
- Théberge, J., Williamson, K. E., Aoyama, N., Drost, D. J., Manchanda, R., Malla, A. K., Northcott, S., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., Pavlosky, W., Densmore, M., Schaefer, B., & Williamson, P. C.
- Affiliations
- Western University (CA)
- McGill University (CA)
- St Joseph's Health Care (CA)
- Corresponding author
- Théberge, Jean
- ORCID
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2007-10
- Volume
- 191
- Issue
- 4
- Pages
- 325-334
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2066003443
- Cited by
- 185
- References
- 42
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 13 · 2014: 16 · 2013: 12 · 2012: 18
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (12078, MT-12078)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- first-episode schizophrenia, gray matter loss, glutamine, thalamus, anterior cingulate cortex, antipsychotic drugs, neurodegeneration, brain volumetric changes, longitudinal brain changes
- MeSH terms
- Adult, Female, Glutamine, Gyrus Cinguli, Humans, Functional Laterality, Longitudinal Studies, Magnetic Resonance Imaging, Male, Magnetic Resonance Spectroscopy, Schizophrenia, Thalamus, Time Factors, Case-Control Studies, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
